Egetis Therapeutics

Board/Management Information • Jun 24, 2020

PRESS RELEASE PledPharma AB

Marie-Louise Alamaa appointed interim CFO at PledPharma

Stockholm, June 24, 2020. PledPharma AB (STO: PLED) today announced that Marie-Louise Alamaa takes on the position as interim CFO at PledPharma. She will join the company in July.

Marie-Louise has extensive experience within finance and controlling from public companies. Her previous positions include CFO at Index Invest International AB, various senior finance positions at Crucell Sweden AB (previously SBL Vaccin AB) and Senior Consultant at the listed gaming company Stillfront Group AB.

She has studied economics at the universities of Uppsala and Stockholm, Sweden, with a particular focus on accounting and auditing.

A process for the recruitment of a permanent CFO have been initiated.

"I am very happy to get Marie-Louise on board at PledPharma. She has a proven track-record of broad and relevant work experience in a listed environment, and with a problem-solving and team-oriented attitude, she will make an excellent addition to the team," said Nicklas Westerholm, CEO, PledPharma.

For further information, please contact: Nicklas Westerholm, CEO Tel. +46 (0)73 354 20 62 nicklas.westerholm@pledpharma.se

The information was submitted for publication, through the agency of the contact persons set out above, at 2020-06-24, 08:00 CET.

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's project PledOx® is a first in class drug candidate and is being developed to prevent nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate Aladote® is a first in class drug candidate and is being developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed, and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/